Close Menu

NEW YORK (GenomeWeb) – HTG Molecular said today that it expects a 46 percent year-over-year increase for its full-year 2018 revenues driven by its early-phase pharma programs.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.